Evolutionary dynamics of carbapenem-resistant *Acinetobacter baumannii* circulating in Chilean hospitals

Andrés Opazo-Capurro^{a,b,#}, Iván San Martín^a, Mario Quezada-Aguiluz^a, Felipe Morales^{a,c}, Mariana Domínguez-Yévenes^a, Celia A. Lima^a, Fernanda Esposito^d, Louise Cerdeira^d, Helia Bello-Toledo^a, Nilton Lincopan^{d,e}, Gerardo González-Rocha^{a,b,#}.

^aLaboratorio de Investigación en Agentes Antibacterianos (LIAA-UdeC), Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Chile

^bMillennium Nucleus for Collaborative Research on Bacterial Resistance (MICROB-R)

^cDepartamento de Farmacia, Facultad de Farmacia, Universidad de Concepción, Chile.

^dDepartment of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo, Brazil

^eDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

Running Head: Carbapenem-resistant *A. baumannii* in Chilean Hospitals

#Address correspondence to: A. Opazo-Capurro, andopazo@udec.cl and G. González-Rocha, ggonzal@udec.cl

ABSTRACT

We analyze the evolutionary dynamics of ninety carbapenem-resistant *Acinetobacter baumannii* (CRAB) isolates collected between 1990 and 2015 in Chile. CRAB were identified at first in an isolate collected in 2005, which harbored the *ISAbal-bla_{OXA-69}* arrangement. Later, OXA-58- and OXA-23-producing *A. baumannii* strains emerged in 2007 and 2009, respectively. This phenomenon was associated with variations in the epidemiology of OXA-type carbapenemases, linked to nosocomial lineages belonging to ST109 (CC1), ST162 (CC79), ST15 (CC15) and ST318 (CC15).

Carbapenem-resistant *Acinetobacter baumannii* (CRAB) has been deemed a critical-priority pathogen by the World Health Organization (WHO) (1). It is normally involved in infections acquired in the intensive care units (ICUs), and is commonly resistant to several antibiotics, including carbapenems (2). Accordingly, OXA-type carbapenemases (OTCs) are the main resistance mechanism to carbapenems in *A. baumannii* (3). While OXA-51-like carbapenemases are chromosomally encoded, the remaining OTCs (OXA-23-like, -24-like, -58-like and -143-like) are frequently plasmid encoded (4, 5). OXA-51-like enzymes can mediate resistance to carbapenems if they are overexpressed when the *ISAbal* element is present upstream of the *bla*_{OXA-51-like} gene (6). CRAB outbreaks are commonly associated to the three predominant clonal complexes (CCs) CC109/1, CC118/2 and CC187/3 (University of Oxford/Institute Pasteur MLST schemes) (7). Although, the clonal complex CC113/CC79 has been predominant in South America; CC104/CC15, CC110/ST25 and CC109/CC1 are also present in this region (8).

The aim of this study was to investigate the evolutionary dynamics of CRAB in Chilean hospitals, where this pathogen has an endemic status.

Ninety non-repetitive *A. baumannii* isolates recovered between 1990 and 2015 were included. They were collected in hospitals from nine different cities throughout Chile, in which the greatest distance between two cities is 2,433 km, representing over 50% of the length of the country.

Antibiotic susceptibility tests were performed to carbapenems, cephalosporins, aminoglycosides, ampicillin/sulbactam, piperacillin/tazobactam, ciprofloxacin, and tetracycline (9). Imipenem (IPM) and meropenem (MEM) MICs were determined following the CLSI guidelines (9). Colistin-resistance was screened using the

SuperPolymyxin media (10). Multidrug-resistant (MDR), extensively-drug resistant (XDR) and pandrug-resistant (PDR) phenotypes were defined as previously described (11, 12).

Genetic relatedness was determined by pulsed-field gel electrophoresis (PFGE) as described earlier (13). Groups with at least three genetically related isolates (>87% similarity) were designated as major PFGE clusters (14). Single-locus *bla*_{OXA-51-like} sequence-based typing (SBT) was carried out as described previously (15). Isolates representative of the main PFGE clusters were subjected to whole-genome sequencing (WGS), and sequence types (STs) were determined (Pasteur's scheme) as published earlier (16).

OTCs genes were screened by multiplex-PCR (17), whereas *bla*_{OXA-51-like} alleles were investigated by PCR and sequencing. *ISAbal-bla*_{OXA-51-like} array was examined by conventional PCR (18). CarbAcinetoNP test was performed on all carbapenem non-susceptible isolates that were negative for *bla*_{OXA} genes (19).

The comprised isolates were grouped into three different periods: P1 (1990-1999, *n*= 27), P2 (2000-2009, *n*= 30), and P3 (2010-2015, *n*= 33). Consequently, carbapenem resistance was confirmed in 56 (62%) isolates, being identified for the first time in 2005 in a strain (A329, P2) carrying the *ISAbal-bla*_{OXA-69} array (Figure 1). XDR, MDR or PDR profiles were displayed by 51 (57%), 28 (31%) and 3 (3%) isolates, respectively. Furthermore, 65 (72%) isolates were non-susceptible to amikacin, whereas 64 (71%) were non-susceptible to gentamicin. Additionally, 32 (36%) isolates exhibited resistance to ampicillin-sulbactam, and 4 (3.6%) were colistin-resistant.

Further, *bla*_{OXA-58} (30%) and *bla*_{OXA-23} (30%) genes were more prevalent and were associated with highest carbapenems MICs (Figure 1). The *ISAbal-bla*_{OXA-219} array was observed in 14 of 56 (25%) CRAB isolates. In this regard, OXA-58-producing isolates

seems to have emerged in 2007, whereas *ISAbal*-OXA-219 and OXA-23 producers arose in 2009, being disseminated among different hospitals.

As expected, no OTC producers were identified in P1. Otherwise, eleven OXA-58-, seven OXA-23-, and four *ISAbal*-*bla*_{OXA-51}-like-positive CRAB isolates were detected in P2 (Figure 1). In P3, a change in the molecular epidemiology of circulating OTCs was observed, where OXA-23 producers (*n*= 11) were predominant, followed by OXA-51-like (associated with *ISAbal*, *n*= 15)- and OXA-58 (*n*= 4)-positive isolates (Figure 1). Interestingly, the CRAB isolate A223 was negative for both CarbAcinetoNP and OTCs PCR. Thus carbapenem-resistance could be mediated by a different mechanism (2).

Four major clusters (I – IV) were identified by PFGE (Figure 1). Cluster I included four carbapenem-susceptible isolates from P1, while cluster II comprised CRABs from 2015 that harbored the OXA-23-like (*n*=3) and *ISAbal*-*bla*_{OXA-219} array (*n*=5), which were collected from two hospitals separated by >1000 km (Figure 1). Cluster III contained three CRABs carrying *bla*_{OXA-23-like} genes and the OXA-51-like variants OXA-51 and OXA-69. Finally, cluster IV included three isolates from three different cities, comprising a single OXA-58-like-producing CRAB (Figure 1). Four isolates were non-typeable.

Fifteen *bla*_{OXA-51}-like variants were identified from SBT, where most prevalent alleles were OXA-51 (*n*= 21), OXA-67 (*n*= 20) and OXA-219 (*n*= 18) (Figure 1). They are not associated to the three predominant international clones (ICs). Furthermore, isolates from PFGE cluster I corresponded to ST109, whereas those from clusters II and III belonged to ST15 and ST162, respectively (Figure 1). In cluster IV, two isolates from P1 belonged to ST109, whereas a single isolate (A462) from P3 corresponded to ST318, which is part of the CC15.

In Chile, CRAB has been responsible for about 26% of ventilator-associated pneumonia (VAP) in hospitalized adults (20), whereas carbapenem-resistance rates are above 66% (21). Our results reveal the evolutionary dynamics of CRAB in the country, focusing on the major carbapenem resistance genes and lineages circulating in hospital settings in a period of 25 years.

Worryingly, XDR isolates were predominant in our collection, including resistance to aminoglycosides and ampicillin/sulbactam, in concordance with previous reports in the country (22). Although the rate of colistin resistance was 3.6%, this percentage is higher than the previously published in 2012 (1.4%) (22), representing an alarming increase to be considered CRAB has been increasing lately worldwide, and our results reveal that initially in Chile it was related to the *ISAbal-bla_{OXA-69}* array identified in 2005, where ISs play an essential role in the regulation of this resistance (23).

Concerning to acquired OTCs, OXA-58-like-producing isolates seem to have emerged in 2007, whereas OXA-23-like producers arose later (3, 24). Significantly, after 2010 a new change in the molecular epidemiology of circulating OTCs was observed, where OXA-23 producers have been predominant and widely disseminated along the country. Additionally, we detected the replacement of certain carbapenem-susceptible clones present in P1, by carbapenem-resistant lineages that began to emerge in the late 2000s. SBT revealed that the CRAB isolates were not related to the major ICs (I-III). The main OXA-51-like variants present were OXA-219, OXA-67 and OXA-51. Of these, OXA-51 has been associated with the CC15 (15), previously detected in Europe, Pakistan and South America, which is considered as a high-risk clone (25). In South America, this CC is categorized as epidemic in Brazil (26), which suggests the dissemination of resistant clones through the region. Otherwise, OXA-67 and OXA-219 are related to less prevalent

ICs (15). Interestingly, OXA-219 was originally identified in 2012 from a single isolate from Chile, being related to the worldwide (WW) clone 4 (27), associated to the *ISAbal-bla_{OXA-219}* array. These results suggest the presence of an endemic lineage (WW4, OXA-219) coexisting with a regional lineage (ST15) in Chile (8, 28), which has been described in Brazil (29) and Ecuador (28).

Other identified lineages included ST109 (CC1), ST162 (CC79), and ST318 (CC15). ST109 has been originally identified in Sweden (30), whereas ST162 and ST318 have been described in Brazil (29, 31). These findings reaffirm that the major lineages present in the region are different to those globally spread (8). However, ICII and III have been lately identified in Peru (32), which might have an important impact on the local epidemiology.

In conclusion, our study provides data about evolutionary dynamics of CRAB circulating in Chilean hospitals, which were linked to particular lineages as well as to the emergence of specific OTCs, whereas colistin resistance deserves an urgent attention to strengthen surveillance.

ACKNOWLEDGMENTS

The authors want to thank to the National Fund for Scientific and Technological Development (FONDECYT) for supporting this study. The authors also want to thank the microbiologists of the hospitals and medical centers who kindly provided the isolates including in this project. N.L. is a research grant fellow of Conselho Nacional de Desenvolvimento Científico (CNPq 312249/2017-9). This work was partially presented at the American Society for Microbiology (ASM) Microbe 2016 meeting, Boston, USA.

CONFLICT OF INTEREST STATEMENT

None to declare.

FUNDING SOURCE.

This work was supported through funds granted by the National Fund for Scientific and Technological Development (FONDECYT) of Chile (project N°3150286), the Universidad de Concepción (project ENLACE-VRID N°216.036.044-1.0), Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil (FAPESP 2016/08593-9) and Conselho Nacional de Desenvolvimento Científico, Brazil (CNPq 462042/2014-6).

REFERENCES.

1. World Health Organization (WHO). 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics.
2. Peleg AY, Seifert H, Paterson DL. 2008. *Acinetobacter baumannii*: emergence of a successful pathogen. Clin Microbiol Rev 21:538–82.
3. Opazo A, Domínguez M, Bello H, Amyes SGB, González-Rocha G. 2012. OXA-type carbapenemases in *Acinetobacter baumannii* in South America. J Infect Dev Ctries 6:311–6.
4. Evans BA, Amyes SGB. 2014. OXA β -lactamases. Clin Microbiol Rev 27:241–263.
5. Evans BA, Hamouda A, Amyes SGB. 2013. The rise of carbapenem-resistant *Acinetobacter baumannii*. Curr Pharm Des 19:223–38.
6. Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, Pitt TL. 2006. The role of IS*Aba1* in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. FEMS Microbiol Lett 258:72–7.
7. Martins N, Picão RC, Cerqueira-Alves M, Uehara A, Barbosa LC, Riley LW, Moreira BM. 2016. A new tri locus sequence-based multiplex-PCR to detect major *Acinetobacter baumannii* clones. Infect Genet Evol 42:41–45.
8. Higgins PG, Dammhayn C, Hackel M, Seifert H. 2010. Global spread of carbapenem-resistant *Acinetobacter baumannii*. J Antimicrob Chemother 65:233–238.
9. Clinical and Laboratory Standards Institute. 2017. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

- 213 10. Nordmann P, Jayol A, Poirel L. 2016. A universal screening culture medium for
214 polymyxin-resistant Gram-negative bacteria. *J Cyst Fibros* 15:1395–1399.
- 215 11. Vikas Manchanda, Sinha Sanchaita NS. 2010. Multidrug Resistant *Acinetobacter*. *J*
216 *Glob Infect Dis* 291–304.
- 217 12. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG,
218 Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB,
219 Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-
220 resistant, extensively drug-resistant and pandrug-resistant bacteria: an international
221 expert proposal for interim standard definitions for acquired resistance. *Clin*
222 *Microbiol Infect* 18:268–81.
- 223 13. Seifert H, Dolzani L, Bressan R, van der Reijden T, van Strijen B, Stefanik D,
224 Heersma H, Dijkshoorn L. 2005. Standardization and interlaboratory reproducibility
225 assessment of pulsed-field gel electrophoresis-generated fingerprints of
226 *Acinetobacter baumannii*. *J Clin Microbiol* 43:4328–35.
- 227 14. Al-Sultan AA, Evans BA, Aboulmagd E, Al-Qahtani AA, Bohol MFF, Al-Ahdal
228 MN, Opazo AF, Amyes SGB. 2015. Dissemination of multiple carbapenem-resistant
229 clones of *Acinetobacter baumannii* in the Eastern District of Saudi Arabia. *Front*
230 *Microbiol* 6:1–7.
- 231 15. Pournaras S, Gogou V, Giannouli M, Dimitroulia E, Dafopoulou K, Tsakris A,
232 Zarrilli R. 2014. Single-locus-sequence-based typing of *bla*_{OXA-51-like} genes for rapid
233 assignment of *Acinetobacter baumannii* clinical isolates to international clonal
234 lineages. *J Clin Microbiol* 52:1653–7.
- 235 16. Larsen M V., Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L,
236 Sicheritz-Pontén T, Ussery DW, Aarestrup FM, Lund O. 2012. Multilocus sequence

- typing of total-genome-sequenced bacteria. J Clin Microbiol 50:1355–1361.
17. Higgins PG, Lehmann M, Seifert H. 2010. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. Int J Antimicrob Agents 35:305.
18. Ruiz M, Marti S, Fernandez-Cuenca F, Pascual A, Vila J. 2007. Prevalence of IS(Aba1) in epidemiologically unrelated *Acinetobacter baumannii* clinical isolates. FEMS Microbiol Lett 274:63–6.
19. Dortet L, Poirel L, Errera C, Nordmann P. 2014. CarbAcineto NP test for rapid detection of carbapenemase- producing *Acinetobacter* spp. J Clin Microbiol 52:2359–2364.
20. Otaíza F, Orsini M, Pohlenz M, Sepúlveda D. 2014. Informe de Vigilancia de Infecciones Asociadas a la Atención en Salud 2014. Ministerio de Salud, Departamento de Calidad y Formación programa Control IAAS 54–56.
21. Instituto de Salud Publica de Chile (ISPCCH). 2015. Boletín de resistencia antimicrobiana. Programa Control Infecciones Asociadas a la atención en salud.
22. Cifuentes M, Silva F, García P, Bello H, Briceño I, Calvo M, Labarca J. 2014. Susceptibilidad Antimicrobiana en Chile 2012. Rev Chil Infectología 31:123–130.
23. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant *Acinetobacter baumannii*. Antimicrob Agents Chemother.
24. Rodríguez CH, Nastro M, Famiglietti A. 2018. Carbapenemases in *Acinetobacter baumannii*. Review of their dissemination in Latin America. Rev Argent Microbiol 13:30178–5.
25. Karah N, Sundsfjord A, Towner K, Samuelsen Ø. 2012. Insights into the global

molecular epidemiology of carbapenem non-susceptible clones of *Acinetobacter baumannii*. Drug Resist Updat 15:237–247.

26. Pagano M, Rocha L, Sampaio JLM, Martins AF, Barth AL. 2017. Emergence of OXA-72-producing *Acinetobacter baumannii* Belonging to High-Risk Clones (CC15 and CC79) in Different Brazilian States. Infect Control Hosp Epidemiol 38:252–254.
27. Zander E, Nemec A, Seifert H, Higgins PG. 2012. Association between β -lactamase-encoding bla(OXA-51) variants and DiversiLab rep-PCR-based typing of *Acinetobacter baumannii* isolates. J Clin Microbiol 50:1900–4.
28. Rodriguez CH, Balderrama N, Nastro M, Nuñez T, Castro G, Magne R, Ugarte T, Valenzuela N, Roach F, Mota MI, Burger N, Velazquez G, Ortellado-Canese J, Bruni G, Pandolfo C, Bastias N, Famiglietti A. 2016. Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* in South America. J Med Microbiol 65:1088–1091.
29. Chagas TPG, Carvalho KR, de Oliveira Santos IC, Carvalho-Assef APDA, Asensi MD. 2014. Characterization of carbapenem-resistant *Acinetobacter baumannii* in Brazil (2008-2011): Countrywide spread of OXA-23-producing clones (CC15 and CC79). Diagn Microbiol Infect Dis 79:468–472.
30. Hamidian M, Nigro SJ, Hall RM. 2017. Problems with the Oxford multilocus sequence typing scheme for *Acinetobacter baumannii*: Do sequence type 92 (ST92) and ST109 exist? J Clin Microbiol 55:2287–2289.
31. Camargo CH, Tiba MR, Saes MR, Mahnic De Vasconcellos F, Fernando L, Santos D, Romero EC, De D, Garcia O. 2016. Population Structure Analysis of Carbapenem-Resistant *Acinetobacter baumannii* Clinical Isolates from Brazil Reveals Predominance of Clonal Complexes 1, 15, and 79. Antimicrob Agents

285 Chemother 60:2545–47.

286 32. Levy-blitchtein S, Roca I, Plasencia-rebata S, Vicente-taboada W, Velásquez-pomar

287 J, Muñoz L, Moreno-morales J, Pons MJ, Valle-mendoza J, Vila J. 2018. Emergence

288 and spread of carbapenem- resistant *Acinetobacter baumannii* international clones II

289 and III in Lima , Peru. Emerg Microbes Infect 7:119.

290

- 1 Figure 1. Dendrogram generated after restriction with *ApaI* enzyme for 86/90 typed *A.*
- 2 *baumannii* isolates. The black dotted line represents 87% similarity. I to IV denote the
- 3 major PFGE groups characterized according to the criteria described in the manuscript.
- 4 MDR: multidrug-resistant; XDR: extensively-drug resistant; PDR: pandrug-resistant; OTC:
- 5 OXA-type carbapenemase; ST: Sequence type; COL: colistin. ● Isolates typified by MLST.